Preview of a Roth-hosted expert webinar examining the ALS treatment landscape, persistent unmet needs, and clinical trial endpoint design.
Key Takeaways
- Webinar will feature Boobalan Pachaiyappan, Jeremy Shefner, and Alon Ben-Noon
- Session will examine PrimeC's mechanism, clinical positioning, and PARAGON Phase 3 goals
- FDA cleared PARAGON Phase 3, which plans roughly 300 US-focused participant enrollments